Why do so many promising cancer drugs fail?
We started with a question that has defined our mission: to build a preclinical model that finally reflects human biology.
Our Story
The Question
Why do 97% of oncology drugs fail in clinical trials? This question drove our founding—a frustration shared by scientists watching promising drugs fail in patients. The answer wasn't the drugs. It was the models.
The Breakthrough
Grounded in landmark research, our team developed a method to preserve the entire tumor tissue architecture. The result is not a model of a tumor. It is a living fragment of the patient's tumor.
The Platform
OrgaNova TRiCBiO was founded to translate this breakthrough into a scalable platform. Today, we have a biobank of 1,500+ models and have validated our clinical prediction accuracy at 84.43%.
World-Class Scientists. Industry-Proven Leaders.
Our Journey
Li, X., Nadauld, L., ..., Kuo, C.J. publish on oncogenic transformation in GI organoids in Nature Medicine (500+ citations).